布伦索卡提布 - - 对于支气管切除症患者的另一种治疗"机会之窗"
Florin-Dumitru Mihălțan1,2, Ruxandra Ulmeanu3, Ancuța-Alina Constantin1,2
1Department of Cardio-Thoracic Pathology, "Carol Davila" University of Medicine and Pharmacy, 050474 Bucharest, Romania.
Journal of clinical medicine
|February 13, 2026
概括
布伦索卡提布 (Brensocatib) 是一种新型的支气管病的治疗方法,通过向中性粒细胞炎症,有效地减少了恶化. 这种治疗在治疗这种慢性肺病方面取得了重大进展.
科学领域:
- 肺部病理学 肺部病理学
- 药理学 药理学是指药理学的学科.
- 免疫学 免疫学 免疫学
背景情况:
- 支气管病是一种慢性呼吸道疾病,其特点是支气管扩张,炎症和反复感染.
- 由中性粒细胞驱动的炎症,由中性粒细胞血清蛋白酶介导,是关键的致病机制.
- 现有的治疗方法往往无法完全解决潜在的炎症.
研究的目的:
- 为了评估brensocatib的疗效和安全性,这是一种新型的二二酶-1 (DPP-1) 抑制剂.
- 评估brensocatib对支气管切除症患者恶化频率和唾液中性粒细胞蛋白酶活性的影响.
- 建立brensocatib作为中性粒细胞介导的呼吸道疾病的向治疗方法.
主要方法:
- 利用了2期WILLOW和3期ASPEN临床试验的数据.
- 给非囊性纤维化支气管切除症患者服用选择性DPP-1抑制剂布伦索卡提布.
- 测量了恶化的速度,到第一个恶化的时间,以及唾液中性粒细胞蛋白酶活性.
主要成果:
- 布伦索卡提布显著降低了支气管切除症恶化的频率.
- 该药物在患者子组中表现出了有利的安全性.
- 在布伦索卡提布治疗时观察到中性粒细胞蛋白酶活性显著下降.
- 当添加到标准护理疗法时,益处是一致的.
结论:
- 布伦索卡提布 (Brensocatib) 是第一个FDA批准的非囊性纤维化支气管病的基于机制的疗法.
- 它代表了对中性粒细胞介导的呼吸道疾病的精确治疗的范式转变.
- 布伦索卡提布显示出降低抗生素依赖和管理其他由中性粒细胞驱动的炎症状况的潜力.
相关概念视频
01:25Antiasthma Drugs: β2-Adrenoceptor Agonists
2.1K
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
2.1K
01:19Antiasthma Drugs: Leukotriene Modifiers
2.2K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
2.2K
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
2.1K
Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
2.1K
01:26COPD: Management Using Bronchodilators and Corticosteroids
1.2K
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
1.2K
01:24Cystic Fibrosis: Management
657
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
657
01:30Asthma-IV: Nursing Management
4.0K
The nursing management of asthma is a comprehensive approach that relies heavily on the expertise and dedication of healthcare professionals. It involves thorough assessment, accurate diagnosis, strategic planning, effective implementation, and diligent evaluation. By meticulously following this step-by-step process, healthcare professionals play a crucial role in providing the best possible care and treatment for patients with asthma, enhancing their overall health and well-being.
First, in...
First, in...
4.0K